Marengo to Unveil First-in-Human Data for its Novel, Selective Dual T Cell Agonist, Invikafusp Alfa (STAR0602) in a Late Breaking Oral Presentation at SITC 2024 Annual Meeting

Marengo’s precision, Vβ chain targeted T cell activator technology reinvigorates anti-tumor immune responses in refractory tumor models Invikafusp alfa is being evaluated as a single-agent in an ongoing Phase 1/2 clinical trial (STARt-001) to treat PD(L)1 resistant “cold” cancers First…